Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 29th Preview)
-
M&A and corporate restructuring
Zymeworks has agreed to buy Theravance Biopharma for $929 million in cash, reshaping the royalty-focused biotech with immediate exposure to commercial respiratory revenue from Yupelri (revefenacin). The deal includes a $350 million non-recourse note from OMERS Life Sciences tied to Yupelri profit share, plus cash from Theravance and Zymeworks, with Theravance shareholders receiving $17 per share. The transaction follows Theravance’s earlier strategic review and a hit from the company’s ampreloxetine Phase 3 failure in multiple system atrophy-related low blood pressure. Zymeworks said the acquisition is designed to diversify its revenue base, strengthen its balance sheet, and fund additional oncology programs. Theravance’s economics include expected commercial milestone payments tied to Trelegy Ellipta sales and additional payouts linked to ampreloxetine licensing or sale. Analysts characterize the offer as a premium to Theravance’s trading levels after the ampreloxetine setback, with Yupelri cash flows positioned to repay deal financing. For investors, the deal underscores how value in late-stage respiratory franchises can translate into near-term liquidity and balance-sheet flexibility, particularly for companies built around royalty streams rather than discovery-to-launch risk.
-
Clinical-stage failures in allergic and skin diseases
Evommune’s Phase 2b trial of EVO756 for chronic spontaneous urticaria (CSU) missed its primary endpoint, sending the stock down sharply and removing a potential challenger to Novartis in the CSU market. The study tested an oral MRGPRX2 antagonist across three doses versus placebo in 160 antihistamine-failed adults. Across the regimen, none of the EVO756 arms produced a statistically larger improvement than placebo on Urticaria Activity Score over seven days (UAS7) at Week 12. Evommune stated the doses were safe and well tolerated, but the lack of placebo-adjusted efficacy reduces confidence that the program can succeed in CSU. The setback leaves Novartis with fewer competitive concerns after its FDA approval of Rhapsido (BTK inhibitor) in CSU in September 2025. Evommune continues to test EVO756 in other itch-related areas, including an ongoing Phase 2b atopic dermatitis study expected to report data in the third quarter, and plans a Phase 2b migraine prevention trial. The outcome highlights how indicator specificity can be decisive in MRGPRX2 antagonism strategies, and how quickly investor expectations can reset after a clean negative readout.
-
Regulatory guidance and AI integration in clinical trials
China’s National Medical Products Administration (NMPA) has issued updated Good Clinical Practice (GCP) regulations that take effect in September, tightening requirements around data governance, privacy, and ethical compliance. The update is the first since 2020 and emphasizes transparent, traceable handling of both paper and electronic clinical trial materials. The revised guideline instructs trial sponsors, CROs, and sites to store and process study data to support reliability and traceability while protecting participants’ personal information in line with China’s personal information protection laws. It also reiterates international ethical anchors, including principles from the Declaration of Helsinki. Separately, the Association of Clinical Research Organizations (ACRO) is urging the FDA to include CROs as direct participants in a proposed AI trial pilot, rather than treating them as subcontractors. ACRO argues CROs have a global line of sight into real-world trial operations and can help regulators balance patient safety, data integrity, and evidentiary standards. Taken together, the moves signal tighter expectations on clinical trial data handling—while also pushing for clearer stakeholder roles as real-time and AI-enabled trial designs expand.
-
Companion diagnostics and MRD in Phase III oncology
Aveta Biomics will use Natera’s Signatera ctDNA test as a minimal residual disease (MRD) endpoint in its Phase III head and neck squamous cell carcinoma program, APG-157. The study will enroll up to 826 patients across resectable and unresectable cohorts and randomize participants to APG-157 versus standard of care. Aveta said the ctDNA assay will be used to assess responses during treatment and to validate molecular findings from an earlier Phase II trial, supporting future regulatory submissions. Signatera has also gained FDA approval as a companion diagnostic for Genentech’s Tecentriq in bladder cancer. The Phase II dataset presented previously at ASCO included pathological response in 77% of patients and tumor shrinkage of at least 30% in four patients, with no Grade 3 or higher adverse events reported. Additional analysis presented at AACR linked APG-157 to reduced HPV viral load and activation of a pathway associated with lower metastasis risk. For MRD-driven oncology strategies, embedding ctDNA readouts into pivotal designs continues to expand the practical role of liquid biopsy assays in differentiation and regulatory evidence packages.
-
Oncology drug discovery deals
Antares has signed a discovery and commercialization collaboration with Novartis targeting small-molecule medicines across oncology targets described as long deemed undruggable. Antares will receive $105 million upfront, with potential milestones up to $1.8 billion and tiered royalties on global net sales. Under the agreement, Antares leads discovery and applies its covalent drug discovery engine—combining screening libraries, chemical proteomics, structure-driven computational chemistry, and machine learning—until Novartis exercises options on specific programs. Novartis positions the deal as an expansion of its approach to oncology discovery where historical target biology has limited conventional chemistry. Antares, founded as a spin-out of Scorpion Therapeutics, launched with a Series A financing in June 2025 after Eli Lilly acquired Scorpion for $2.5 billion. The company will continue advancing independent cancer and other indication candidates alongside the Novartis work. The structure emphasizes staged risk-sharing for early discovery while giving a major pharma partner a pipeline-building route into challenging oncology biology.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.